Summary:
In adults with type 2 diabetes, exenatide and glucagon co-infusion significantly increased myocardial glucose uptake and improved markers of diastolic dysfunction compared to no exenatide-glucagon treatment, though it was associated with transient gastrointestinal side effects.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes (T2D), a population with increased risk of heart failure and metabolic complications. |
| Intervention | Co-infusion of exenatide (GLP-1 receptor agonist) and glucagon. |
| Comparison | Absence of exenatide and glucagon co-infusion (control condition). |
| Outcome | Exenatide and glucagon co-infusion significantly increased myocardial glucose uptake and improved markers of diastolic dysfunction. These benefits were accompanied by transient gastrointestinal side effects. |
Source: James Goodman, et al. “Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.” Read article here.
